Shares of Viking Therapeutics fell greater than 30% in premarket buying and selling Tuesday after the corporate launched mid-stage trial information on its weight problems tablet that dissatisfied buyers.
The outcomes may very well be a blow to Viking, which was as soon as seen as a scorching M&A goal as pharmaceutical firms scramble to affix the booming marketplace for weight problems and diabetes medication. It may reinforce Eli Lilly and Novo Nordisk‘s dominance within the area, particularly as they develop tablets for weight reduction that might enter the market years forward of the pill formulation of Viking’s drug, VK2735.
Jared Holz, Mizuho well being care fairness strategist, mentioned in an e-mail Tuesday that the information “in all probability shutters hope for [Viking] to be a bigtime participant within the oral weight problems market over the close to to medium time period.”
The race to develop a extra handy weight problems tablet has been fraught, as firms similar to Pfizer have needed to scrap earlier contenders and convey forth new ones.
Viking’s once-daily tablet helped sufferers lose as much as 12.2% of their weight at round three months. The corporate additionally mentioned that weight reduction did not plateau, which implies sufferers may lose much more in a longer-term examine.
It is tough to immediately examine the tablet’s part two trial information to the outcomes of oral medication additional alongside in growth, together with remedies developed by Eli Lilly and Novo Nordisk.
Holz added that the outcomes on Viking’s tablet “look inferior” to these of Eli Lilly’s oral drug “on nearly all metrics.” The very best dose of Eli Lilly’s each day tablet helped sufferers lose 12.4% of their physique weight, or 11.2% no matter discontinuations, at 72 weeks in a part three trial.
Holz pointed to the excessive charge of sufferers who discontinued Viking’s drug for any motive over 13 weeks, which was round 28%. In the meantime, round 1 / 4 of individuals discontinued Eli Lilly’s tablet, orforglipron, for any motive over 72 weeks.
That is “a for much longer trial and due to this fact [Lilly] seems much better head-to-head,” Holz mentioned.
Viking mentioned the commonest causes for sufferers to discontinue therapy have been gastrointestinal unwanted effects, the vast majority of which have been gentle to average in severity and noticed earlier in therapy. However round 58% of sufferers on the tablet reported experiencing nausea and 26% skilled vomiting, in comparison with 48% and 10%, respectively, amongst those that took a placebo.
These facet impact charges over a shorter trial interval seem like worse than these seen in trials on Eli Lilly’s tablet and the oral model of Novo Nordisk’s weight reduction drug Wegovy.
Viking’s therapy works by imitating two naturally produced intestine hormones known as GLP-1 and GIP.
GLP-1 helps cut back meals consumption and urge for food. GIP, which additionally suppresses urge for food, might also enhance how the physique breaks down sugar and fats.
Eli Lilly’s tablet and the oral model of Novo Nordisk’s Wegovy each goal GLP-1, however the latter has dietary restrictions.
